Neurology

One Family, Many Paths: Subtypes and Targeted Therapies

At a Glance

CDG is a family of over 160 genetic conditions, making a precise diagnosis essential. While the most common type (PMM2-CDG) relies on supportive care, a few rare CDG subtypes can be treated with highly targeted dietary sugars like mannose or galactose under strict medical supervision.

Think of CDG not as a single disease, but as a large “family” of over 160 distinct genetic conditions ^[1]. Because each subtype is caused by a different genetic instruction error, a treatment that works for one type might be completely ineffective—or even harmful—for another ^[2]. This is why getting a “precision diagnosis” through genetic testing is the most important step in your child’s care ^[3]^[4].

The Common Pathway vs. Rare Solutions

While all CDG types involve errors in how the body processes sugars, the “glitch” can happen at many different points in the assembly line.

PMM2-CDG (The Most Common Type): This is the “face” of the CDG family, but it currently does not have a standard, approved dietary sugar therapy. Research is focused on small molecule drugs and gene therapy to try and boost the activity of the faulty enzyme ^[5]^[6]. Management for PMM2-CDG is primarily supportive, focusing on physical therapy and monitoring for heart or liver issues ^[7]^[8].
Targeted Therapy Subtypes: For a very small number of CDG types, doctors can “bypass” the genetic glitch by giving the body extra doses of a specific sugar or mineral ^[2]. It is important to note that these treatable subtypes represent only a tiny fraction of the 160+ known CDGs.

Subtypes with Targeted Dietary Therapies

For the following subtypes, the specific genetic error allows for a “work-around” using dietary supplements. These must only be used under strict medical supervision, as dosages must be precise and monitored via blood tests.

Subtype	Targeted Therapy	Why it Works
MPI-CDG	Mannose	This sugar bypasses the blocked enzyme and allows the cell to continue building its sugar chains ^[2]^[9].
PGM1-CDG	Galactose	Extra galactose helps provide the “fuel” the body needs to properly finish the glycosylation process ^[2]^[10].
TMEM165-CDG	Galactose + Manganese	A combination of sugar and minerals can help restore balance to the cell’s “shipping department” ^[2]^[11].
SLC35A2-CDG	Galactose	Adding galactose helps correct “bald spots” on proteins where sugar chains were missing ^[10]^[12].

Why Precision Matters

If a child has PMM2-CDG, taking mannose (the treatment for MPI-CDG) has not been shown to help and may cause unwanted side effects ^[2]^[13]. The treatment plan is entirely dictated by the biochemical pathway affected.

For the vast majority of CDG subtypes, there is no “magic sugar” yet ^[7]. In these cases, the “treatment” is a dedicated team of specialists who manage the symptoms, such as:

Neurologists to monitor for seizures or “stroke-like episodes” ^[14].
Gastroenterologists to ensure proper nutrition and weight gain ^[15].
Hematologists to watch for clotting or bleeding risks ^[16].

Research is moving faster than ever, with new drugs (like epalrestat for PMM2-CDG) and gene therapies entering clinical trials, offering hope for more targeted treatments in the future ^[5]^[6]. Learn more about managing symptoms in Building Your Child’s Care Team.

Common questions in this guide

Why is finding the exact CDG subtype so important?

CDG is actually a family of over 160 distinct genetic conditions. Because the genetic error differs in each type, a targeted treatment that works well for one subtype might be completely ineffective or harmful for another.

What are targeted dietary therapies for CDG?

For a very small number of CDG subtypes, doctors can bypass the genetic error using specific dietary sugars like mannose or galactose. These supplements provide the body with the fuel or work-arounds needed to finish processing sugars.

Can I give my child with PMM2-CDG mannose supplements?

No. Mannose is a targeted treatment for a specific subtype called MPI-CDG. Taking mannose for PMM2-CDG has not been shown to help and may actually cause unwanted side effects. Dietary therapies must be tailored to the specific biochemical pathway affected.

How is PMM2-CDG treated?

PMM2-CDG is primarily managed with supportive care from a team of specialists who monitor for heart, liver, and neurological issues. However, researchers are actively studying new options, including small molecule drugs like epalrestat and gene therapy.

Curated prompts to bring to your next appointment.

1.Based on my child's genetic mutation, are they a candidate for targeted dietary therapies like mannose or galactose?
2.If we start a dietary therapy, how will we monitor its effectiveness? Will we use specific biomarkers or repeat blood tests like transferrin IEF?
3.What are the potential side effects of specific supplements for my child, and how do we ensure it doesn't affect their liver or blood sugar?
4.For PMM2-CDG, are there any upcoming clinical trials or experimental small-molecule treatments (like epalrestat) that we should be aware of?
5.Since most CDG management is supportive, can you help us prioritize which specialists my child needs to see first?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References (16)

1
Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry to Detect Diagnostic Glycopeptide Markers of Congenital Disorders of Glycosylation.
Wada Y
Mass spectrometry (Tokyo, Japan) 2020; (9(1)):A0084 doi:10.5702/massspectrometry.A0084.
PMID: 32547898
2
Diagnostic and Therapeutic Approaches in Congenital Disorders of Glycosylation.
Raynor A, Lebredonchel É, Foulquier F, et al.
Handbook of experimental pharmacology 2025; (288()):211-241 doi:10.1007/164_2025_745.
PMID: 40119203
3
Frontiers in congenital disorders of glycosylation consortium, a cross-sectional study report at year 5 of 280 individuals in the natural history cohort.
Lam C, Scaglia F, Berry GT, et al.
Molecular genetics and metabolism 2024; (142(4)):108509 doi:10.1016/j.ymgme.2024.108509.
PMID: 38959600
4
Congenital disorders of glycosylation.
Chang IJ, He M, Lam CT
Annals of translational medicine 2018; (6(24)):477 doi:10.21037/atm.2018.10.45.
PMID: 30740408
5
AAV9-based PMM2 gene replacement augments PMM2 expression and improves glycosylation in primary fibroblasts of patients with phosphomannomutase 2 deficiency (PMM2-CDG).
Zhong M, Balakrishnan B, Guo AJ, Lai K
Molecular genetics and metabolism reports 2024; (38()):101035 doi:10.1016/j.ymgmr.2023.101035.
PMID: 38130891
6
Sorbitol Is a Severity Biomarker for PMM2-CDG with Therapeutic Implications.
Ligezka AN, Radenkovic S, Saraswat M, et al.
Annals of neurology 2021; (90(6)):887-900 doi:10.1002/ana.26245.
PMID: 34652821
7
Neurodevelopmental profiles of 14 individuals with phosphomannomutase deficiency (PMM2-CDG).
Weixel T, Adedipe D, Muldoon G, et al.
Journal of inherited metabolic disease 2025; (48(1)):e12782 doi:10.1002/jimd.12782.
PMID: 39105373
8
Clinical severity and cardiac phenotype in phosphomannomutase 2-congenital disorders of glycosylation : Insights into genetics and management recommendations.
Holubova V, Barone R, Grunewald S, et al.
Journal of inherited metabolic disease 2025; (48(1)):e12826 doi:10.1002/jimd.12826.
PMID: 39633515
9
A Case of Congenital Disorder of Glycosylation Type 1b Presenting as Hyperinsulinemic Hypoglycemia and Failure to Thrive.
Rani S, Sahai I, Misra M
JCEM case reports 2023; (1(5)):luad109 doi:10.1210/jcemcr/luad109.
PMID: 37908211
10
Clinical and biochemical improvement with galactose supplementation in SLC35A2-CDG.
Witters P, Tahata S, Barone R, et al.
Genetics in medicine : official journal of the American College of Medical Genetics 2020; (22(6)):1102-1107 doi:10.1038/s41436-020-0767-8.
PMID: 32103184
11
Nutritional Therapies in Congenital Disorders of Glycosylation (CDG).
Witters P, Cassiman D, Morava E
Nutrients 2017; (9(11)) doi:10.3390/nu9111222.
PMID: 29112118
12
Intact transferrin and total plasma glycoprofiling for diagnosis and therapy monitoring in phosphoglucomutase-I deficiency.
Abu Bakar N, Voermans NC, Marquardt T, et al.
Translational research : the journal of laboratory and clinical medicine 2018; (199()):62-76 doi:10.1016/j.trsl.2018.04.008.
PMID: 30048639
13
Unsuccessful intravenous D-mannose treatment in PMM2-CDG.
Grünert SC, Marquardt T, Lausch E, et al.
Orphanet journal of rare diseases 2019; (14(1)):231 doi:10.1186/s13023-019-1213-3.
PMID: 31640729
14
Stroke-Like Episodes in PMM2-CDG: When the Lack of Other Evidence Is the Only Evidence.
Serrano M
Frontiers in pediatrics 2021; (9()):717864 doi:10.3389/fped.2021.717864.
PMID: 34708008
15
Complex Phenotypes in Inborn Errors of Metabolism: Overlapping Presentations in Congenital Disorders of Glycosylation and Mitochondrial Disorders.
Gardeitchik T, Wyckmans J, Morava E
Pediatric clinics of North America 2018; (65(2)):375-388 doi:10.1016/j.pcl.2017.11.012.
PMID: 29502919
16
Coagulation abnormalities in a prospective cohort of 50 patients with PMM2-congenital disorder of glycosylation.
De Graef D, Ligezka AN, Rezents J, et al.
Molecular genetics and metabolism 2023; (139(2)):107606 doi:10.1016/j.ymgme.2023.107606.
PMID: 37224763

This page provides educational information about CDG subtypes and targeted therapies. Always consult your child's medical genetics team before starting any dietary supplements like mannose or galactose, as improper use can be harmful.

Get notified when new evidence is published on Congenital disorder of glycosylation.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents